DelveInsight’s Myelofibrosis market report provides an in-depth understanding of Myelofibrosis, historical and forecasted epidemiology, as well as Myelofibrosis market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also discusses current Myelofibrosis treatment practices and algorithms, as well as Myelofibrosis market drivers, Myelofibrosis market barriers, and unmet medical needs.
Some of the Key Highlights from the Myelofibrosis Market Report
- The Myelofibrosis incidence was found to be 0.5 cases per 100,000 people in the research conducted in Northern European countries.
- According to the National Institute of Health, Primary Myelofibrosis is a rare disease that affects around 1 in 500,000 people globally.
- Key pharmaceutical companies working diligently in the development of the therapies for Myelofibrosis treatment include Suzhou Zelgen Biopharmaceuticals, Sierra Oncology, Inc., Kartos Therapeutics, Prelude Therapeutics, Karyopharm Therapeutics Inc, and others.
- Karyopharm Therapeutics Inc is undertaking a phase II multicenter, two-arm, open-label trial in people with Myelofibrosis who have received at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor to evaluate the safety and efficacy of selinexor versus treatment per physician’s choice (PC).
- Zelgen is developing Jaktinib tablets for Myelofibrosis treatment.
- The other therapies which are in pipeline for the Myelofibrosis treatment include Momelotinib (Sierra Oncology, Inc.), KRT-232 (Kartos Therapeutics), PRT543 (Prelude Therapeutics), along with others.
Want to learn more? Request for the sample @ Myelofibrosis Life Expectancy
The Myelofibrosis market report covers current treatment practices, emerging drugs, Myelofibrosis market share of individual therapies, as well as current and forecasted Myelofibrosis market Size from 2018 to 2030, segmented by seven major markets.
Myelofibrosis: Overview
Myelofibrosis (MF) is a condition in which normal bone marrow tissue gradually deteriorates and is replaced by fibrous scar-like material. It is a type of chronic leukemia that belongs to a group of blood disorders known as myeloproliferative diseases. This causes progressive bone marrow failure over time. Under normal circumstances, the bone marrow provides a fine network of fibers for stem cells to divide and grow on. These fibers are produced by fibroblasts, which are specialized cells in the bone marrow. Myelofibrosis can be of two types: Primary Myelofibrosis and Secondary Myelofibrosis.
Myelofibrosis Epidemiology Segmentation
The Myelofibrosis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
- Myelofibrosis Total Incident Cases
- Myelofibrosis Age-Specific Incident Cases
- Myelofibrosis Type-Specific Incident Cases
- Myelofibrosis Diagnosed and Treatable Cases
Get the complete epidemiology analysis @ Myelofibrosis Cell Therapy
Myelofibrosis Treatment Landscape
Since the cause of Primary Myelofibrosis is unknown, treatment focuses on the symptoms that each patient is experiencing. The current treatment options for Myelofibrosis include:
- Janus-associated kinase (JAK) inhibitors
- Immunomodulators
- Hormonal therapies and other approaches like Radiation therapy and splenectomy
- Chemotherapies and combination Drugs
Apart from this, Jakafi (ruxolitinib) (Incyte Corp.) and INREBIC (fedratinib) (Celgene’s) are the FDA-approved drugs for the treatment of people with intermediate or high-risk myelofibrosis, including primary myelofibrosis.
Myelofibrosis Market
The dynamics of the Myelofibrosis market are expected to change in the coming years as a result of advancements in diagnosis methodologies, increased disease awareness, and increased healthcare spending globally, as well as the launch of emerging therapies such as Momelotinib, KRT-232, PRT543, and others during the forecast period of 2021–2030.
Myelofibrosis Pipeline Therapies and Key Companies
- Jaktinib hydrochloride tablets: Suzhou Zelgen Biopharmaceuticals
- Momelotinib: Sierra Oncology, Inc.
- KRT-232: Kartos Therapeutics
- PRT543: Prelude Therapeutics
- Selinexor: Karyopharm Therapeutics Inc
For further information on the emerging drugs, visit Myelofibrosis Treatment Therapy
Myelofibrosis Market Drivers
- Increasing Myelofibrosis Incidence
- Improved awareness on Myelofibrosis and other oncological diseases
Myelofibrosis Market Barriers
- High cost involved in treatment might restrict the growth of the global myelofibrosis market
- Lack of development in the treatment of MF-associated anemia
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Myelofibrosis Key Companies: Suzhou Zelgen Biopharmaceuticals, Sierra Oncology, Inc., Kartos Therapeutics, Prelude Therapeutics, Karyopharm Therapeutics Inc, among others.
Myelofibrosis Key Pipeline Therapies: Jaktinib hydrochloride tablets, Selinexor, Momelotinib, KRT-232, PRT543, and others.
Myelofibrosis Segmentation: By Geography, Myelofibrosis drugs
Analysis: Comparative and conjoint analysis of Myelofibrosis emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
| 1. | Report Introduction |
| 2. | Executive Summary |
| 3. | Myelofibrosis Market Overview at a Glance |
| 4. | Disease Background and Overview: Myelofibrosis |
| 5. | Myelofibrosis Case Reports |
| 6. | Myelofibrosis Epidemiology Methodology |
| 7. | Myelofibrosis Epidemiology and Patient Population |
| 8. | Myelofibrosis: Country-Wise Epidemiology |
| 9. | Myelofibrosis Treatments & Medical Practices |
| 10. | Myelofibrosis Emerging Therapies |
| 11. | Myelofibrosis Market Size |
| 12. | 7MM Myelofibrosis: Country-Wise Market Analysis |
| 13. | Myelofibrosis Market Drivers |
| 14. | Myelofibrosis Market Barriers |
| 15. | SWOT Analysis |
| 16. | Myelofibrosis Market Access and Reimbursement |
| 17. | Appendix |
| 18. | Report Methodology |
| 19. | DelveInsight Capabilities |
| 20. | Disclaimer |
| 21. | About DelveInsight |
Know more about report offerings @ Myelofibrosis Market Share
Related Reports
DelveInsight’s “Primary Myelofibrosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Primary Myelofibrosis, historical and forecasted epidemiology as well as the Primary Myelofibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Post Polycythemia Vera Myelofibrosis Market
Get comprehensive historical and forecast analysis of Post Polycythemia Vera Myelofibrosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Sierra Oncology Inc., CTI Biopharma Corp., Incyte Corporation, Hoffmann-La Roche, among others.
Primary Myelofibrosis Pipeline Insights
“Primary Myelofibrosis Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market.
Get comprehensive historical and forecast analysis of Acute Myeloid Leukemia Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Pfizer, Abbvie, Astellas Pharma, among others.
Chronic Phase Chronic Myeloid Leukemia Market
DelveInsight’s “Chronic Phase Chronic Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Phase Chronic Myeloid Leukemia, historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Get comprehensive historical and forecast analysis of Myocarditis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Cardiol Therapeutics, among others.
Get comprehensive historical and forecast analysis of Multiple Myeloma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Johnson & Johnson, Amgen, BioLineRx, Bristol-Myers Squibb, ExCellThera, Pfizer, Takeda, Precision BioSciences, Poseida Therapeutics, among others.
Adult T-Cell Leukemia-Lymphoma Market
DelveInsight’s “Adult T-Cell Leukemia-Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Adult T-Cell Leukemia-Lymphoma, historical and forecasted epidemiology as well as the Adult T-Cell Leukemia-Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Chronic Periodontitis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Periodontitis, historical and forecasted epidemiology as well as the Chronic Periodontitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Get comprehensive historical and forecast analysis of Hairy Cell Leukemia Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Roche, Innate Pharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187
Connect With Us at:
Contact Information:
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187
The post The Dynamics of the Myelofibrosis Market are expected to transform positively in the upcoming years owing to an increase in global healthcare spending and influx of key companies appeared first on Financial Market Brief.
